论文部分内容阅读
目的分析乙肝病毒基因型和抗病毒治疗与胰岛素抵抗的关系及临床意义。方法设计型特异引物,采用基因型特异引物聚合酶链反应(PCR)对乙肝患者进行分型,分析乙肝病毒基因型之间及抗病毒治疗前后胰岛素抵抗程度的差异。结果130例乙肝患者中,基因型B型胰岛素抵抗率为27.47%,基因型C型患者胰岛素抵抗率为28.57%,基因型B、C混合型患者胰岛素抵抗率为18.18%,未检出A、D、E、F、G、H基因型,检出的3种基因型患者间差异无统计学意义(P>0.05);54名患者抗病毒治疗后空腹血糖、胰岛素及胰岛素抵抗指数与治疗前相比差异均有统计学意义(P<0.05)。结论重庆地区乙肝患者乙肝病毒基因型与胰岛素抵抗无显著相关性;抗病毒治疗似可改善患者胰岛素抵抗。
Objective To analyze the relationship between hepatitis B virus genotype, antiviral therapy and insulin resistance and its clinical significance. Methods Genotype-specific primers were used to genotype hepatitis B patients by genotype-specific primer polymerase chain reaction (PCR) to analyze the differences in the degree of insulin resistance between hepatitis B virus genotypes and before and after antiviral therapy. Results Among 130 hepatitis B patients, the genotype B insulin resistance rate was 27.47%, the genotype C genotype insulin resistance rate was 28.57%, the genotype B and C mixed genotypes insulin resistance rate was 18.18% The genotypes of D, E, F, G and H were not significantly different between the three genotypes (P> 0.05). The fasting blood glucose, insulin and insulin resistance index of 54 patients were significantly higher than those before treatment Compared with the difference was statistically significant (P <0.05). Conclusion There is no significant correlation between hepatitis B virus genotypes and insulin resistance in patients with hepatitis B in Chongqing. Antiviral therapy may improve insulin resistance in patients.